The Myotonic Dystrophy Foundation is pleased to announce that the U.S. Senate has, for the first time ever, included myotonic dystrophy as part of the Department of Defense’s premier biomedical research program – the Peer-Reviewed Medical Research Program.
Tom McPeek was an award-winning dog trainer and a corrections professional before his DM2 kicked in.
Make a gift to MDF during our Giving Tuesday campaign and double the impact of your donation! Thanks to the generosity of the Haylon and Lord families, MDF will match all gifts made now through December 5th, up to the first $10,000 raised. Give now and significantly increase your support of Care and a Cure for myotonic dystrophy families around the world!
CRISPR is an exploratory strategy with potential for treatment of RNA-triggered diseases. Will DNA or RNA targeting prove to be the best approach for DM?
Genetic and epigenetic mechanisms drive differences between CDM and DM1—a new study elucidates downstream signaling pathways that underlie their diverse phenotypes and represent putative therapy development targets for CDM.